Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
174 hedge funds and large institutions have $365M invested in Verve Therapeutics in 2024 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 62 increasing their positions, 46 reducing their positions, and 24 closing their positions.
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
35% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 46
5% more funds holding
Funds holding: 166 → 174 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $372M → $365M (-$7.11M)
1.7% less ownership
Funds ownership: 90.65% → 88.95% (-1.7%)
65% less call options, than puts
Call options by funds: $414K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$14M |
| 2 |
Millennium Management
New York
|
+$6.34M |
| 3 |
CC
Casdin Capital
New York
|
+$5.44M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.25M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$17.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$12.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.31M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.64M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$5.44M |
VERV Hedge Fund Activity: Q3 2024 in Review
174 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2024, worth a combined $365M — down 1.9% from $372M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VERV positions and 24 closed out — a net gain of 9 holders — while 62 added to existing stakes and 46 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $14M. The largest seller was ARK Investment Management, exiting entirely with an estimated $17.1M sold.
- 174 institutional investors held Verve Therapeutics (VERV) as of Q3 2024, up from 166 in Q2 2024.
- Funds reported $365M of Verve Therapeutics stock for Q3 2024, down 1.9% quarter-over-quarter.
- 33 funds opened new Verve Therapeutics positions in Q3 2024 and 24 closed out, a net change of +9 holders.
- The largest Verve Therapeutics buyer in Q3 2024 was Schonfeld Strategic Advisors, an estimated $14M added.
- The largest Verve Therapeutics seller in Q3 2024 was ARK Investment Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q3 2024.